<DOC>
	<DOC>NCT00348192</DOC>
	<brief_summary>The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's Disease. SB-742457 is a new treatment which is thought to increase the levels of certain chemicals in the brain that are often decreased in patients with Alzheimer's Disease.</brief_summary>
	<brief_title>SB-742457 And Donepezil In Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion criteria: Clinical diagnosis of probable mildtomoderate Alzheimer's Disease as determined by the NINCDSADRDA and DSMIV criteria with an MMSE score of 1224. Subjects and their caregivers must provide informed consent prior to study entry. Adequate blood pressure and laboratory values. Exclusion criteria: Females of childbearing potential. Have other causes of dementia such as vascular damage, depression, bipolar affective disorder, schizophrenia, syphilis, vitamin B12 deficiency or thyroid deficiency. Subjects taking medication for Alzheimers disease or centrally acting agents which might impact study outcomes. Subjects taking agents for which there is a theoretical risk of interaction with SB742457 or donepezil. Subjects with conditions which might be exacerbated by exposure to donepezil. Subjects with known hypersensitivity to sunlight or seizures.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Alzheimer's Disease</keyword>
	<keyword>cognition global functioning</keyword>
	<keyword>symptomatic</keyword>
	<keyword>SB-742457</keyword>
</DOC>